

Organized by



Supported By



An Initiative By



05 May, 2023 (Friday)



14:30 - 15:30 Hrs Singapore Time



HALL A



In-Person

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

14:30 - 14:40

Local Therapy

Speaker: WONG NAN SOON, SINGAPORE

- **GS4-02:** Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04/EUBREAST-06/OMA study
- **GS4-01:** Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer – Results from ACOSOG Z11102 (Alliance)
- **GS4-04:** Population-based Estimates of Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2

14:40 - 14:45

Local Therapy

Speaker: FAYE LIM, SINGAPORE

- **GS4-05:** Phase 2 Randomized Trial of Conventional versus Hypofractionated Post-Mastectomy Proton Radiotherapy
- **GS5-12:** Hypofractionated Radiotherapy in Patients with Breast Cancer (HRBC): Acute Toxicity Data of a Phase III Randomized Study

14:45 - 15:00

Early Breast Cancer

Speaker: VIRGINIA KAKLAMANI, USA

- **GS5-01:** Addition of Platinum to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
- **GS1-05:** Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates
- **GS1-09:** Abemaciclib Plus Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer: Results from a Pre-Planned MonarchE Overall Survival Interim Analysis, including 4-year Efficacy Outcomes
- **GS5-10:** Utility of the 70-gene MammaPrint Test for Prediction of Extended Endocrine Therapy Benefit in Patients with Early-Stage Breast Cancer in the IDEAL Trial

apbcs.org

Organized by



Supported By



An Initiative By



05 May, 2023 (Friday)



14:30 - 15:30 Hrs Singapore Time



HALL A



In-Person

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

15:00 - 15:15

Advanced Breast Cancer ER Positive HER2 Negative

Speakers: SHAHEENAH DAWOOD, UAE

- **GS1-10:** Primary Results from the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER2- Advanced Breast Cancer Treated with Ribociclib + Endocrine Therapy vs Physician's Choice Combination Chemotherapy
- **GS3-01:** EMERALD Phase 3 Trial of Elacestrant versus Standard of Care Endocrine Therapy in Patients with ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
- **GS3-02:** Camizestrant, a Next Generation Oral SERD vs Fulvestrant in Post-Menopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer: Results of the Randomized, Multi-dose Phase 2 SERENA-2 Trial
- **GS3-04:** Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-Resistant Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results from the Phase III CAPitello-291 Trial

15:15 - 15:30

Survivorship/ Advanced Breast Cancer Antibody Drug Conjugates

Speaker: HOPE RUGO, USA

- **GS4-09:** Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13)
- **GS1-11:** Sacituzumab Govitecan (SG) vs Treatment of Physician's Choice (TPC): Efficacy by Trop-2 Expression in the TROPICS-02 Study of Patients (Pts) With HR+/HER2- Metastatic Breast Cancer (mBC)
- **GS2-01:** Trastuzumab Deruxtecan vs Physician's Choice in Patients with HER2+ Unresectable and/or Metastatic Breast Cancer Previously Treated with Trastuzumab Emtansine: Primary Results of the Randomized, Phase 3 Study DESTINY-Breast02
- **GS2-02:** Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Updated Survival Results of the Randomized, Phase 3 Study DESTINY-Breast03

apbcs.org